Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids
The FEBS Journal · 2025
DOI: 10.1111/febs.70069 ↗At a glance
Journal article in The FEBS Journal, 2025. Written by Alessandra Lo Cicero and 6 co-authors. Institution: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy. Major MEDLINE topics: Spheroids, Cellular, Extracellular Matrix, Breast Neoplasms. Cited 14 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of University and Research (MUR) for the PON Project on Research and Innovation 2014-2020 (Azione IV.4-Contratti di ricerca su tematiche dell'Innovazi…, European Union-NextGenerationEU through the Italian Ministry of University and Research under PNRR-MUR.
Abstract (original language)
Solid tumors have a complex extracellular matrix (ECM) that significantly affects tumor behavior and response to therapy. Understanding the ECM's role is crucial for advancing cancer research and treatment. This study established an in vitro model using primary cells isolated from a rat breast tumor to generate three‐dimensional spheroids. Monolayer cells and spheroid cultures exhibited different protein expression patterns, with primary tumor spheroids presenting an increased level of ECM‐related proteins and a more complex extracellular environment. Furthermore, spheroids produce endogenous collagen type I matrix, which is the main component of the tumoral ECM. This matrix is arranged predominantly around the 3D structure, mimicking the conditions of solid tumors. Treatments with recombinant collagenases class II (acting on the linear collagen region) and class I (acting on the 3D‐helix region) completely degrade collagen within the spheroid structure. Collagenase pretreatment enhances the accessibility of the anticancer drug doxorubicin to penetrate the core of spheroids and sensitize them to doxorubicin‐induced cytotoxicity. Our findings highlight the importance of overcoming drug resistance in breast cancer by targeting the ECM and proposing a novel strategy for improving therapeutic outcomes in solid tumors. By employing a three‐dimensional spheroid model, with an endogenous ECM, we can offer more relevant insights into tumor biology and treatment responses.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy.
- Department of Biomedical Engineering Bioscience Center of the University of Cincinnati, OH, USA.
- Department of Pharmacy, University of Copenhagen, Denmark.
- Abiel Srl, Palermo, Italy.
- Proteomics Group of Ri.MED Foundation, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.
ORCID profiles: Alessandra Lo Cicero, Simone Dario Scilabra, Giulio Ghersi
Funding
- Ministry of University and Research (MUR) for the PON Project on Research and Innovation 2014-2020 (Azione IV.4-Contratti di ricerca su tematiche dell'Innovazi…
- European Union-NextGenerationEU through the Italian Ministry of University and Research under PNRR-MUR
Cite
APA
Lo Cicero, A., Campora, S., Lo Buglio, G., Cinà, P., Lo Pinto, M., Scilabra, S. D., & Ghersi, G. (2025). Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids. The FEBS Journal. https://doi.org/10.1111/febs.70069
Vancouver
Lo Cicero A, Campora S, Lo Buglio G, Cinà P, Lo Pinto M, Scilabra SD, et al. Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids. The FEBS Journal. 2025. doi:10.1111/febs.70069
BibTeX
@article{LoCicero2025,
author = {Lo Cicero, Alessandra and Campora, Simona and Lo Buglio, Gabriele and Cinà, Paolo and Lo Pinto, Margot and Scilabra, Simone Dario and Ghersi, Giulio},
title = {Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70069}
}
EUVIMED